Acquires BASF’s Pharmaceutical manufacturing contract business and related facility at Shreveport, Louisiana Acquires Dowpharma’s small molecule business at its Mirfield and Cambridge facilities, UK.

Becomes No.1 pharmaceutical company in India in turnover and profitability. Launches Reditux ™ (Rituximab) – the World’s first biosimilar of a monoclonal antibody Blaglitazone (DRF 2593) enters Phase III of clinical trials becoming India’s most advanced NCE

Revenues touch USD 1 Billion in December 2006. Dr. Reddy's obtains its second 180-day marketing exclusivity for a generic drug in the US market with the launch of Ondenesetron Hydrochloride Tablets. Becomes an Authorized Generic Partner for Merck’s Proscar® & Zocor® in the US market during 180 day exclusivity period. Acquires betapharm- the fourth-largest generics company in Germany for a total enterprise value of € 480 million.

Acquires Roche's API Business at the state-of-the-art manufacturing site in Mexico with a total investment of USD 59 million. Announces India's first major co-development and commercialization deal for it's molecule Balaglitazone (DRF 2593), with Rheoscience. Announces a unique partnership for the commercialization of ANDAs with ICICI Venture.

Acquires Trigenesis gives access to drug delivery technology platforms

Announces a 15-year exclusive product development and marketing agreement for OTC drugs with Leiner Health Products in the US Launches Ibuprofen, first generic product to be marketed under the “Dr. Reddy’s” label in the US

Conducts its first overseas acquisition – BMS Laboratories Limited and Meridian Healthcare in UK

Becomes the first Asia Pacific pharmaceutical company, outside Japan, to list on the New York Stock Exchange. Listed with the symbol ‘RDY’ on April 11, 2001. Out-licenses DRF 4158 to Novartis for up to US $55 million upfront payment Launches its first generic product, Ranitidine, in the US market Becomes the first Indian pharmaceutical company to obtain an 180-day exclusive marketing rights for a generic drug in the US market with the launch of Fluoxetine 40 mg capsules on August 3, 2001

Dr. Reddy's Laboratories becomes India's third largest pharmaceutical company with the merger of Cheminor Drugs Limited, a group company Reddy US Therapeutics, a wholly-owned subsidiary, is established at Atlanta, US to conduct target based drug discovery

Acquisition of American Remedies Limited, a pharmaceutical company based in India.

Licenses anti-diabetic molecule, DRF 2725 (Ragaglitazar), to Novo Nordisk

Licenses anti-diabetic molecule, DRF 2593 (Balaglitazone), to Novo Nordisk. Becomes the first Indian pharmaceutical company to out-license an original molecule. First ANDA filed with the United States Food and Drug Administration for Ranitidine

Sets up of a Joint Venture in Russia.

Makes a GDR issue of USD 48 million Foundation stone laid for a finished dosages facility to cater to the highly regulated markets such as the US.

Dr. Reddy's Research Foundation established. The company's drug discovery programme starts.

First formulation exports to Russia commence

Dr. Reddy’s, for the first time in India, exports Norfloxacin and Ciprofloxacin to Europe and Far East.

Acquires Benzex Laboratories Pvt. Limited to expand its Bulk Actives business.

Obtains its first USFDA approval for Ibuprofen API Starts its formulations operations

Dr. Reddy’s goes public Dr. Reddy’s listed on Bombay Stock Exchange (BSE) Dr. Reddy’s enters international markets with exports of Methyldopa

Dr Anji Reddy establishes Dr. Reddy's Laboratories with an initial capital outlay of Rs.25 lakhs